A Study on Peginterferon Alfa-2b Combined With NAs in Compensated HBV Cirrhosis

Exclusion Criteria

• •1. Decompensated liver cirrhosis, hepatic failure, or hepatocellular carcinoma; presence of other liver diseases such as fatty liver disease, alcoholic liver disease, drug-induced liver injury, autoimmune liver disease, or Wilson's disease;
• •2. History of clinically significant diseases of the cardiovascular, hematological and lymphatic, respiratory, urinary, endocrine, immune, psychiatric, or nervous systems (e.g., epilepsy), ophthalmic diseases, or thyroid-related disorders;
• •3. Pregnancy, lactation, or intention to become pregnant during the study period;
• •4. Known or suspected allergy to the investigational product(s) or any of its excipients;
• •5. Participation in any other interventional clinical trial within 3 months prior to screening or planning to participate in another clinical trial during the study;
• •6. Any other condition considered by the investigator to be inappropriate for participation in the study.